Author

Eric K. Park

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

OpenAlex ID: A5012969986

Oral HIF-2α inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease

2021 · Henry E. Wiley, Hanna R. Coleman, et al. · Investigative Ophthalmology & Visual Science · 6

Works count: 1

Citation count: 6

H-index: 1

I10-index: